The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
What a tube
Ndn, you are wrong.
If AS and team know that AVA6k activated in the Tumor with very little elsewhere, then it doesn't matter that's its just 1 patient, it very much strengthens proof of concept.
Very good point CO!
If the early data really is 'very pleasing' there could well be a very early mover on the partening play. I'm sure that Avacta can disclose early data to possible partners (under nda) prior to disclosing to the market thus interested partners can make an educated risk/reward decision at a very early stage. Or they could wait, but to wait and risk Avacta releasing breakthrough data to the entire world will see the 'buy-in' price explode through all out bidding war!
Food for thought but an early mover based on early positive data would not surprise.
I would not be surprised to see some serious action over the coming weeks as Institutions and possible future partners start to join the dots on the trial progress.
Good point, Wiggly. If the patient sits within this profile and has now had 3 x high dosages, that is clearly quite material.
Logically, you would start with such a candidate profile as it gives clear forward guidance.
Consider all of the eyes on this trial... Avacta won't last for 2 weeks post update of positive trial data.
Hoping that the BB can confirm
Dose 1 is 90% of standard dose?
Dose 2 is?
Dose 3 is?
Idiot sturgeon I believe still requires pcr for Scottish clubs
Leeds United. Was confirmed few months back. I think they posted on twitter.
Avacta probably prevented from naming due to nda on the buyer side
If the end of year read out remains positive there will be a long queue of acquirers / licensees looking to get on board immediately. They will not wait until the trial completes
The patient has been dosed 3 times with high dosage and its very obvious from the AS comments that the results are extremely positive. AS admitted though that this was just 1 patient and results with others could be different (unlikely though).
There is no shortage of patients waiting and we will now rapidly move to 3 new trial sites.
Couldnt have wished for better
Ignore the trolls, including Ophidian (trolls work both ways) and just read and digest the update. As a long term holder I'm delighted with progress and never been more confident.
AffiDX® SARS-CoV-2 Antigen Lateral Flow Test
During the reporting period the Company completed the clinical validation of the AffiDX® SARS-CoV-2 antigen lateral flow test which was shown to have 100% sensitivity for clinical samples with Ct=27 (considered as a high to medium infectious viral load) and 98% sensitivity for clinical samples with Ct values up to 31 (low viral load) obtained from 98 positive COVID-19 patients. The clinical specificity was 99% obtained from 102 negative samples. Additional data (a further 134 negative samples) obtained more recently has further defined the clinical specificity to be 99.6%.
First patient has now had all 3 doses!
Neutrino, not true, he said HUA submitted and awaiting response.
Looking forward to seeing the headlines in 40m time!
Thought about this also. Clearly, much better value to buy Avacta as a whole rather than see the current deal through to royalties.
With that said, perhaps terms of the agreement prevent LG from acquiring Avacta?
Back to 200+ if true.
Wyn,
Avacta updated the signifcant shareholders last month and still have Confier holding 2.99%.